Scientific Advisory Board


Dr. George L. Bakris M.D., Hon. DSc

Dr. Bakris has published over 700 peer-reviewed articles and book chapters in the areas of diabetic kidney disease, hypertension and progression of nephropathy. He currently serves as a special government expert to the Centers for Medicare & Medicaid Services (CMS) and the FDA Cardiovascular and Renal Drugs Advisory Committee. He chaired the first National Kidney Foundation Consensus report on blood pressure and impact on renal disease progression, and served on many national guideline committees, including the American Diabetes Association Clinical Practice Guideline Committee. Previously, he served as the President of the American College of Clinical Pharmacology and the American Society of Hypertension. Dr. Bakris received his medical degree from the Rosalind Franklin School of Medicine. He completed his residency in Internal Medicine at the Mayo Graduate School of Medicine and completed fellowships in Nephrology and Clinical Pharmacology at the University of Chicago.

Dr. Csaba P. Kovesdy, M.D.

Dr. Kovesdy has published research in over 260 peer-reviewed articles, in addition to numerous abstracts and book chapters. His research interests in nephrology are centered on epidemiology and outcomes, cardiovascular risk factors, metabolic abnormalities, and race-ethnicity, in addition to bone and mineral disorders in pre-dialysis chronic kidney disease. He is currently the Principal Investigator on several studies in these areas and frequently lectures at both national and international medical conferences. Dr. Kovesdy obtained his medical degree from the University of Pécs Medical School in Hungary, and completed his internal medicine residency at the Henry Ford Hospital in Detroit. He then completed his nephrology fellowship at the Johns Hopkins Bayview Medical Center in Baltimore. He is a Fellow of the American Society of Nephrology, and a member of the International Society of Nephrology.

Dr. Julia Lewis, M.D.

Dr. Lewis is a nephrology specialist and researcher, holding multiple roles on the executive committee of the Collaborative Study Group (CSG) for the past twenty years. She has served as head of several NIH and industry-sponsored oversight and advisory panels and has published research in over 200 peer-reviewed journals. She currently sits on the FDA Cardiovascular and Renal Drugs Advisory Committee and as the Principal Investigator at the Vanderbilt Nephrology and Renal Transplant Clinic, she has led protocol and form design, intervention, hypertension management, outcome classification and publication committees.

She is the Principal Investigator for the ongoing PYR-311 (CSG-17) Phase 3 study. Dr. Lewis received her medical degree from the University of Illinois at Chicago. She also completed fellowships at the University of Texas and completed her residency at the Michael Reese Hospital in Chicago.

Dr. Peter A. McCullough, M.D., M.P.H.

Dr. McCullough directs cardiovascular education and research for the Baylor Health Care System and functions as Vice Chief of Medicine at Baylor University Medical Center. He is a Principal Faculty in internal medicine for the Texas A&M University Health Sciences Center and is an expert on the role of chronic kidney disease as a cardiovascular risk state, with over 1,000 publications. His works have appeared in multiple medical journals including the New England Journal of Medicine and Journal of the American Medical Association. In 2013, he was honored with the International Vicenza Award for Critical Care Nephrology for his outstanding contribution and dedication to the emerging problem of cardiorenal syndromes. Dr. McCullough is the current Chair of KEEP, the National Kidney Foundation’s Kidney Early Evaluation Program, which is the nation’s largest community screening effort for chronic diseases. He received his medical degree from University of Texas Southwestern Medical School and completed his internal medicine residency at the University of Washington in Seattle. He completed a cardiology fellowship as Chief Fellow at William Beaumont Hospital, and received a master’s degree in public health from the University of Michigan.

Dr. Chirag R. Parikh, M.D.

Dr. Parikh conducts an active patient-oriented research program investigating the translational and epidemiological aspects of acute kidney injury (AKI) and other kidney-related disorders. He is the Founder and Principal Investigator of the NIH-sponsored Translational Research Investigating Biomarker Endpoints in Acute Kidney Injury (TRIBE-AKI) consortium, which has conducted three large studies for validating novel kidney injury biomarkers in cardiac surgery, kidney transplantation and hepatorenal syndrome settings. Currently, he is also developing biomarkers for diabetic kidney disease using archived samples from large diabetes trials including VA-NEPHRON-D and ACCORD. Dr. Parikh has authored more than 150 peer-reviewed papers, 50 book chapters and reviews, and has given numerous lectures at scientific meetings and academic institutions. He has received the National Junior Physician Investigator Award from the American Federation of Medical Research and the Outstanding Investigator Award from the Society of Clinical Investigation. He received his medical degree from the University of Mumbai and completed his residency in internal medicine at Nassau University and SUNY in Stony Brook. He completed a fellowship in Nephrology and Hypertension at the University of Colorado Health Sciences Center, where he also received a PhD in Clinical Investigation and Translational Research.

J. Wesley Fox, Ph.D.

Co-Founder and Advisor, NephroGenex